
Keywords: نیمه عمر حذف ترمینال; anti-infectives; bioavailability; clinical pharmacokinetics; formulation; oral absorption; pharmacokinetics; HCV; hepatitis C virus; GT; genotype; DAA; direct-acting antiviral; RBV; ribavirin; GLE; glecaprevir; PIB; pibrentasvir; Cmax; maximum plasma conc